The purpose of this research study is to evaluate effectiveness and potential side effects of taking the test medicine versus a placebo to prevent recurrent Clostridium difficile infection (CDI). The test medicine, CP101, has not been approved by the FDA to treat or prevent recurrent CDI; its use in this study is investigational. By comparing people's responses to the placebo and to the test medicine being studied, researchers can tell whether the test medicine is having any benefit to prevent recurrent CDI.
Thank you for your interest, but this study is not currently enrolling.
North Carolina (Statewide)
Stomach, Digestion and Gut Health